Hepatitis-C

  • The hepatitis C virus as it appears under a transmission electron microscope. Photo by BSIP/UIG Via Getty Images

    WASHINGTON — Your money or your life?

    Sovaldi, a new pill for hepatitis C, cures the liver-wasting disease in 9 of 10 patients, but treatment can cost more than $90,000.

    Leading medical societies recommend the drug as a first-line treatment, and patients are clamoring for it. But insurance companies and state Medicaid programs are gagging on the price. In Oregon, officials propose to limit how many low-income patients can get Sovaldi. Continue reading

  • Inside of a Gilead Sciences Lab
    April 23, 2014  

    A new drug has a 90 to 100 percent chance of curing the Hepatitis-C virus, but costs tens of thousands of dollars for a course of treatment. The announcement by the manufacturer that it earned more than $2 billion in the year’s first quarter raises the question, who should pay when drugs are highly effective, but extremely expensive? Hari Sreenivasan reports on the profits, coverage and costs. Continue reading